One Of America's Largest Cannabis Companies Exits Pennsylvania Amid Financial Troubles, Lays Off 76 Employees

Zinger Key Points
  • Goodblend Pennsylvania LLC, a subsidiary of Parallel Cannabis opted to exit the medical marijuana market in the Keystone State.
  • The company is closing its cannabis dispensaries in Friendship and Erie and a Pittsburgh processing facility, laying off 76 workers.

Goodblend Pennsylvania LLC, a subsidiary of the privately held, vertically integrated company Parallel Cannabis, opted to exit the medical marijuana market in the Keystone State.

What Happened

The cannabis operator announced this week that it's closing its two cannabis dispensaries in Friendship and Erie and a processing facility in Pittsburgh, which cost its 76 workers their jobs, reported Pittsburgh Post-Gazette.

"In connection with a strategic review, we have made the decision to withdraw from the Pennsylvania market in order to serve patients in our other, more established markets," Sam Schwartz, a Parallel spokesman, told the Post-Gazette.

What's Next

Goodblend notified the state that it would discontinue its operations effective September 15.

In an emailed statement, the company said they seek to provide their personnel "with support during this transition."

"Parallel/Goodblend is working with regulators to establish and execute a closure plan over the next 60 days," the company said.

The Background

According to Green Market Report, the move comes on the heels of financial difficulties that prompted a lawsuit from the company's landlord, Innovative Industrial Properties Inc. IIPR.

Parallel and Innovative are entangled in a legal dispute in the local court this month. Parallel allegedly breached a 20-year lease agreement for its Beaver Avenue facility, having failed to make the monthly rent since November of 2022, owing roughly $6 million in total.

MMJ Research Partnership With Pitt

On a more positive note, Parallel also announced it has partnered with the University of Pittsburgh over a clinical research program. The deal was approved by the Pennsylvania Department of Health in 2020.

The 10-year collaboration between the medical school and Parallel, and its subsidiary Goodblend, will provide $3 million to study the safety and efficacy of medical cannabis. Their efforts will be focused on sickle cell disease, chronic pain and generalized anxiety disorders.

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo: Courtesy of Kindel Media by Pexels

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsLegalMarketsGoodblend Pennsylvania. medical marijuanaParallel CannabisSam Schwartz
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.